Stroke Trials

Is galantamine safe, tolerable, and potentially efficacious in improving long-term functional and cognitive outcomes in patients with aneurysmal subarachnoid hemorrhage when administered during early and subacute stages?

Does a liberal red-cell transfusion strategy, as compared with a restrictive strategy, result in a lower risk of an unfavorable neurologic outcome at 12 months in critically ill adults with acute aneurysmal subarachnoid hemorrhage and anemia?

Does left atrial appendage closure safely decrease the risk of bleeding associated with oral anticoagulants while maintaining a low risk of stroke among patients with atrial fibrillation who have undergone catheter ablation and are at moderate or high risk for stroke?

Does intravenous tenecteplase administered within 4.5 hours of symptom onset improve visual outcomes compared to oral aspirin in patients with acute central retinal artery occlusion?

Does intravenous tenecteplase (0.25 mg/kg) administered within 24 hours of symptom onset improve functional outcome compared with standard medical treatment in patients with ischaemic stroke due to basilar artery occlusion?

Is there an optimal day within the first 14 days to initiate a direct oral anticoagulant after atrial fibrillation-associated ischemic stroke that minimizes the composite risk of ischemic or hemorrhagic events?

Does adding intravenous tenecteplase before thrombectomy improve functional independence at 90 days in patients with acute ischemic stroke due to large-vessel occlusion?

Is NOAC monotherapy noninferior to combination therapy with NOAC plus clopidogrel in patients with atrial fibrillation who had drug-eluting stent implantation at least 1 year earlier?

In survivors of intracerebral haemorrhage with atrial fibrillation, do DOACs reduce the risk of ischaemic stroke without substantially increasing the risk of recurrent intracerebral haemorrhage compared with no anticoagulation?

Is 0° head positioning superior to 30° head positioning at maintaining clinical stability in patients with large vessel occlusion stroke who are candidates for thrombectomy?

In persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, is treatment with oral semaglutide superior to placebo for reducing major adverse cardiovascular events?

Does thrombectomy improve functional outcomes compared to medical management alone in patients with medium vessel occlusion stroke and moderate-to-severe deficits (NIHSS ≥6) presenting within 24 hours?

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation?

Is IV tenecteplase plus endovascular thrombectomy (TNK + EVT) associated with better 3-month functional outcomes compared with EVT alone in patients with anterior circulation LVO stroke treated within 4.5 hours, and does any benefit vary with expected onset-to-thrombolysis time or admission center type?

Does middle meningeal artery embolisation (MMAe) reduce the composite of surgical drainage need, poor clinical outcome, or clinical deterioration compared to observation alone in mildly symptomatic chronic subdural haematoma patients?

Does adding catheter ablation to standard edoxaban therapy reduce the risk of recurrent ischemic stroke or composite cardiovascular outcomes in patients with nonvalvular atrial fibrillation and a recent history of ischemic stroke?

Does early intensive blood pressure lowering reduce cerebral swelling in patients with acute ischemic stroke treated with thrombolysis?

Does minocycline, in addition to routine treatment, improve 90-day functional outcomes compared with placebo in patients with acute ischaemic stroke presenting within 72 hours of symptom onset?

In patients with acute LVO stroke without atrial fibrillation or intracardiac thrombus, which cardiac CT findings are independently associated with a cardioembolic stroke aetiology?

Is off-label intravenous thrombolysis safe and effective in patients with acute ischemic stroke who have recently taken direct oral anticoagulants? Does DOAC reversal with idarucizumab before IVT improve safety or efficacy outcomes?

Does loberamisal, a dual-acting neuroprotective agent, improve functional recovery when administered within 48 hours of moderate to severe acute ischemic stroke?

Does middle meningeal artery (MMA) embolization reduce the rate of chronic subdural hematoma (CSDH) recurrence in patients who underwent an operation and are at high risk of recurrence?

In patients with acute ischemic stroke undergoing endovascular thrombectomy under general anesthesia, does early extubation (<6 hours) improve 90-day functional outcomes compared with delayed extubation (6-12 hours)?

Does lepodisiran, an siRNA targeting hepatic production of lipoprotein(a), safely and effectively reduce serum lipoprotein(a) concentrations over time?

Among patients with asymptomatic high-grade carotid stenosis, does adding carotid revascularization (stenting or endarterectomy) to intensive medical management provide greater benefit than intensive medical management alone in preventing stroke?

What are the new clinical (ischemic stroke, intracranial/major extracranial bleeding, or death) and new MR-Imaging outcomes (ischemic or hemorrhagic brain lesions) between 3 and 6 months in patients with symptomatic, MR-imaging-verified cervical artery dissection treated with aspirin versus anticoagulation?

Does revascularization reduce stroke risk when added to optimized medical therapy in patients with asymptomatic or low-to-intermediate risk symptomatic carotid stenosis?

Are direct oral anticoagulants (DOACs) as safe and effective as vitamin K antagonists (VKAs) for the treatment of cerebral venous thrombosis?

Is the Contour Neurovascular System safe and effective for the treatment of unruptured intracranial bifurcation aneurysms?

Can left atrial appendage closure replace NOACs for stroke prevention in anticoagulation-eligible AF patients?

To determine whether time to treatment influences the effect of intraarterial thrombolysis (IAT), intravenous thrombolysis (IVT), and conservative standard therapy (CST) on visual outcomes in nonarteritic central retinal artery occlusion (CRAO).

Does tirzepatide improve obstructive sleep apnea severity and associated complications in adults with moderate-to-severe OSA and obesity?